Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection

OBJECTIVES: Baloxavir marboxil (formerly S-033188) is a first-in-class, orally available, cap-dependent endonuclease inhibitor licensed in Japan and the USA for the treatment of influenza virus infection. We evaluated the efficacy of delayed oral treatment with baloxavir marboxil in combination with...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Antimicrob Chemother
Main Authors: Fukao, Keita, Noshi, Takeshi, Yamamoto, Atsuko, Kitano, Mitsutaka, Ando, Yoshinori, Noda, Takahiro, Baba, Kaoru, Matsumoto, Kazumi, Higuchi, Naoko, Ikeda, Minoru, Shishido, Takao, Naito, Akira
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6376846/
https://ncbi.nlm.nih.gov/pubmed/30476172
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jac/dky462
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados